Protocol Ledger

NCT06377852 · Phase III · RECRUITING

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Interventional Phase III clinical trial protocol NCT06377852 sponsored by American Society of Clinical Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-29 Enrollment: 500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06377852
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06377852
Protocol FieldVerified Registry Value
NCT IdentifierNCT06377852
Consolidated Lead SponsorAmerican Society of Clinical Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment500 participants (ESTIMATED)
Registered Start Date2024-10-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06377852
Hospital Research SiteLocationSite Profile
Providence Medical FoundationSanta Rosa, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI